Patents by Inventor Valeria R. Fantin

Valeria R. Fantin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210214387
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: March 17, 2021
    Publication date: July 15, 2021
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • Patent number: 11028120
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: June 8, 2021
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai, Chien-Hung Yeh
  • Publication number: 20210147472
    Abstract: The present invention relates generally to formulations and methods for treating cancer. Provided herein are formulations comprising substituted steroidal derivatives. The subject formulations are useful for the treatment of cancer.
    Type: Application
    Filed: April 11, 2019
    Publication date: May 20, 2021
    Inventors: Valeria R. FANTIN, Qiuping YE, Belinda DE LEON, Daqing SUN, Sunil V. MHASKAR
  • Publication number: 20210130390
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: December 8, 2020
    Publication date: May 6, 2021
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • Publication number: 20210130389
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: October 29, 2020
    Publication date: May 6, 2021
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • Publication number: 20210122730
    Abstract: Described herein are glucocorticoid receptor modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: April 10, 2018
    Publication date: April 29, 2021
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Yosup REW, Daqing SUN, Qiuping YE, Haiying ZHOU, Hiroyuki KAWAI, Jared MOORE, Johnny PHAM, Kejia WU, Liusheng ZHU, Dennis YAMASHITA
  • Publication number: 20210047359
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 18, 2021
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai
  • Publication number: 20210023095
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: December 22, 2016
    Publication date: January 28, 2021
    Inventors: Daqing SUN, Lawrence R. MCGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Haiying ZHOU, Minna Delarae BALBAS, Valeria R. FANTIN
  • Publication number: 20210017219
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: September 30, 2020
    Publication date: January 21, 2021
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Valeria R. FANTIN, Haiying ZHOU, Minna Delarae BALBAS
  • Publication number: 20210017220
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: December 22, 2016
    Publication date: January 21, 2021
    Inventors: Daqing SUN, Lawrence R. MCGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Haiying ZHOU, Minna Delarae BALBAS, Valeria R. FANTIN
  • Publication number: 20210002324
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: December 22, 2016
    Publication date: January 7, 2021
    Inventors: Daqing SUN, Lawrence R. MCGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Haiying ZHOU, Minna Delarae BALBAS, Valeria R. FANTIN
  • Patent number: 10836789
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: November 17, 2020
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Valeria R. Fantin, Haiying Zhou, Minna Delarae Balbas
  • Publication number: 20200347090
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: November 2, 2018
    Publication date: November 5, 2020
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Erica L. JACKSON, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA
  • Publication number: 20200291058
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: June 1, 2020
    Publication date: September 17, 2020
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Valeria R. FANTIN, Haiying ZHOU, Minna Delarae BALBAS
  • Patent number: 10723759
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: July 28, 2020
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Valeria R. Fantin, Haiying Zhou, Minna Delarae Balbas
  • Publication number: 20200093844
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: May 9, 2018
    Publication date: March 26, 2020
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Erica L. JACKSON, Daqing SUN, Qiuping YE, Jared MOORE
  • Publication number: 20200055892
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: September 5, 2019
    Publication date: February 20, 2020
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Valeria R. FANTIN, Haiying ZHOU, Minna Delarae BALBAS
  • Publication number: 20190218246
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: March 26, 2019
    Publication date: July 18, 2019
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Valeria R. FANTIN, Haiying ZHOU, Minna Delarae BALBAS
  • Patent number: 7919261
    Abstract: The invention disclosed herein describes novel biomarkers useful for risk assessment, screening, prognosis and selection and monitoring of therapy for HDAC mediated cell proliferative disorders. In particular, the invention provides the identities of three particular proteins whose expression patterns are strongly predictive of a particular patient's treatment outcome, e.g., non-responsiveness to SAHA. The expression profile, or pattern, whether embodied in nucleic acid expression, protein expression, or other expression formats will find use in identifying and selecting patients afflicted with a particular HDAC mediated cancer who are likely to be non-responsive to SAHA-based therapy and thus candidates for other treatments.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: April 5, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Valeria R. Fantin, Jacqueline W. Pierce, Andrey Loboda
  • Publication number: 20090304594
    Abstract: The invention disclosed herein describes novel biomarkers useful for risk assessment, screening, prognosis and selection and monitoring of therapy for HDAC mediated cell proliferative disorders. In particular, the invention provides the identities of three particular proteins whose expression patterns are strongly predictive of a particular patient's treatment outcome, e.g., non-responsiveness to SAHA. The expression profile, or pattern, whether embodied in nucleic acid expression, protein expression, or other expression formats will find use in identifying and selecting patients afflicted with a particular HDAC mediated cancer who are likely to be non-responsive to SAHA-based therapy and thus candidates for other treatments.
    Type: Application
    Filed: December 1, 2006
    Publication date: December 10, 2009
    Inventors: Valeria R. Fantin, Jacqueline W. Pierce, Andrey Loboda